HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING

• US 20110293692A1
• Filed: 05/24/2011
• Published: 12/01/2011
• Est. Priority Date: 05/27/2010
• Status: Active Grant

• Current Assignee: Covidien LP (Medtronic Plc)
• Original Assignee: Covidien LP (Medtronic Plc)
• Inventors: Lavigne, Kevin, Bennett, Steven, Mast, Nathaniel, Skalla, Walter
• Granted Patent: US 8,591,929 B2
• Time in Patent Office: Days
• US Class Current: 424/447
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61L 2300/00 Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
• CPC Class Codes: A61L 31/145 Hydrogels or hydrocolloids
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders

Abstract

The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Claims

1. A method for attaching mesh to tissue comprising:

forming a mixture comprising a first reactive precursor comprising a multi-arm polyether possessing electrophilic groups, a second reactive precursor comprising nucleophilic groups, and at least one initiated precursor comprising at least one vinyl group;

contacting a mesh with a tissue comprising a surface;

injecting the mixture through the mesh and into the tissue;

allowing the mixture to form a first hydrogel both underneath and on the tissue surface in contact with the mesh; and

forming an attachment device for attaching the mesh to the tissue by contacting the initiated precursor with an initiator to form a second hydrogel.

2. The method of claim 1, wherein the mixture further comprises at least one reactive precursor having electrophilic groups in combination with a second reactive precursor having nucleophilic groups.

3. The method of claim 1, wherein the initiated precursor is selected from the group consisting of acrylic acid, methacrylic acid, phosphorylcholine containing monomers, furanone functional vinyl monomers, potassium sulfopropyl acrylate, potassium sulfopropyl methacrylate, n-vinyl pyrrolidone, hydroxyethyl methacrylate, vinyl monomers having a high refractive index, siloxane functional vinyl compounds, polyethylene glycol-silicone co-monomers having vinyl groups, tris acrylate, pyrrole, liquid crystalline vinyl monomers, liquid crystalline vinyl polymers, and combinations thereof.

4. The method of claim 1, wherein the initiator is selected from the group consisting of redox initiators, free radical initiators, radiation, and combinations thereof, to further crosslink the second hydrogel.

5. The method of claim 4, wherein the radiation is selected from the group consisting of heat, visible light, ultraviolet light, gamma ray, and electron beam.

6. The method of claim 1, wherein the attachment device further comprises a bioactive agent.

7. The method of claim 1, wherein the initiated precursor comprises from about 40% to about 90% by weight of the attachment device.

8. The method of claim 1, wherein the first hydrogel has a modulus of from about 10 kPa to about 50 kPa, and the second hydrogel has a modulus of from about 60 kPa to about 200 kPa.

9. The method of claim 1, wherein the first hydrogel degrades over a period of from about 1 day to about 7 days, and the second hydrogel degrades over a period of at least about 6 months.

10. A method comprising:

forming a mixture comprising a first reactive precursor comprising a multi-arm polyether possessing electrophilic groups, a second reactive precursor comprising nucleophilic groups, and at least one initiated precursor comprising at least one vinyl group;

injecting the mixture into a tissue comprising a surface;

allowing the mixture to form a hydrogel both underneath and on the tissue surface; and

contacting a medical device with the mixture.

11. The method of claim 10, wherein the initiated precursor is contacted with an initiator prior to contacting the medical device with the mixture.

12. The method of claim 10, wherein the initiated precursor is contacted with an initiator after contacting the medical device with the mixture.

13. The method of claim 10, wherein the first reactive precursor comprises a core selected from the group consisting of polyethylene glycol, polyethylene oxide, polyethylene oxide-co-polypropylene oxide, co-polyethylene oxide block copolymers, co-polyethylene oxide random copolymers, and combinations thereof, and wherein the second reactive precursor comprises a core comprising a component selected from the group consisting of polyethylene glycol, polyethylene oxide, polyethylene oxide-co-polypropylene oxide, co-polyethylene oxide block copolymers, co-polyethylene oxide random copolymers, polyvinyl alcohol, poly(vinyl pyrrolidinone), poly(amino acids), dextran, chitosan, alginates, carboxymethylcellulose, oxidized cellulose, hydroxyethylcellulose, hydroxymethylcellulose, hyaluronic acid, albumin, collagen, casein, gelatin, and combinations thereof.

14. The method of claim 10, wherein the first reactive precursor possesses N-hydroxysuccinimide groups and the second reactive precursor possesses amine groups.

15. The method of claim 10, wherein the initiated precursor is selected from the group consisting of acrylic acid, methacrylic acid, phosphorylcholine containing monomers, furanone functional vinyl monomers, potassium sulfopropyl acrylate, potassium sulfopropyl methacrylate, n-vinyl pyrrolidone, hydroxyethyl methacrylate, vinyl monomers having a high refractive index, siloxane functional vinyl compounds, polyethylene glycol-silicone co-monomers having vinyl groups, tris acrylate, pyrrole, liquid crystalline vinyl monomers, liquid crystalline vinyl polymers, and combinations thereof.

16. The method of claim 10, wherein the initiator is selected from the group consisting of redox initiators, free radical initiators, radiation, and combinations thereof, to further crosslink the second hydrogel.

17. The method of claim 16, wherein the radiation is selected from the group consisting of heat, visible light, ultraviolet light, gamma ray, and electron beam.

18. The method of claim 10, wherein the mixture further comprises a bioactive agent.

19. The method of claim 10, wherein the initiated precursor comprises from about 40% to about 90% by weight of the mixture.

20. The method of claim 10, wherein the medical device is selected from the group consisting of sutures, staples, tacks, clips, rivets, and combinations thereof.